Is there a tirzepatide oral tablet available in the UK?

Step 1, understand what tirzepatide actually is and why it still comes as a jab

Tirzepatide is the active ingredient in Mounjaro, made by Eli Lilly. It works by activating two gut-hormone receptors simultaneously (GIP and GLP-1) which together slow how quickly the stomach empties, reduce appetite, and help regulate blood sugar. That dual mechanism is why it sits apart from older GLP-1 medicines, and it is described in detail on the tirzepatide overview page.

The reason it is an injection rather than a tablet comes down to chemistry. Like all GLP-1 class medicines, tirzepatide is a large peptide molecule that stomach acid would simply break apart if swallowed in a conventional form. Oral semaglutide gets around this by pairing the drug with an absorption enhancer called SNAC; a similar solution for tirzepatide has not yet reached the market in the UK. Eli Lilly is running early-phase work on an oral tirzepatide formulation, but nothing is approved or commercially available here. The NHS patient information on tirzepatide confirms the injection as the sole licensed form.

In practice, most people adapt quickly to the once-weekly KwikPen. The pen delivers four doses (one per week) from a single device, refrigerated between uses. Administration takes about thirty seconds at home.

Step 2 (see where oral GLP-1 treatment actually stands in the UK today

If the appeal of a tablet is real for you) no needles, no cold-chain storage, easier to pack for a holiday or slip into a bag on a busy Monday morning, that preference is entirely understandable. The good news is that an oral GLP-1 option for weight management now exists in the UK.

On 11 June 2026, the MHRA approved Wegovy tablets, an oral form of semaglutide co-formulated with an absorption enhancer. It was the first oral GLP-1 medicine licensed anywhere in Europe for weight management, and the UK received the approval first. The dosing schedule starts at 1.5 mg daily and escalates through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month spent at each level. There is no refrigeration requirement, which makes day-to-day storage straightforward. For a fuller picture of how it compares to the injection, the oral weight-loss options in the UK page sets out the practical differences clearly.

Wegovy tablets are not the same as Rybelsus. Rybelsus contains the same molecule (semaglutide) but is licensed for type 2 diabetes at much lower doses (3 mg, 7 mg, 14 mg). It is not licensed for weight management and should not be used for that purpose.

Step 3, check whether tirzepatide or oral semaglutide might suit your situation

Because no oral tirzepatide tablet exists in the UK, the choice for people who want an oral route is currently oral semaglutide (Wegovy tablets). The choice between that and the Mounjaro injection turns on a few practical and clinical factors.

Mounjaro's trial results are the strongest published so far: SURMOUNT-1, a 72-week study involving 2,539 adults, recorded average weight reductions of around 20–21% at the 15 mg dose. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight loss than semaglutide 2.4 mg weekly. Wegovy tablets, tested in the OASIS 4 trial over 64 weeks, showed approximately 13.6% average weight loss in the full trial population, rising to around 17% among participants who adhered fully throughout.

Neither figure is a prediction for any individual. A prescriber weighs up your health history, current medicines, and practical circumstances before recommending anything. If the absence of needles is the main factor, that is worth raising directly in a consultation, it is one of the questions our clinical team hears regularly. You can read more about how the two treatment types compare on the Mounjaro vs tablet options page.

Step 4, what to do if you want to start treatment now

Both Mounjaro (tirzepatide injection) and Wegovy tablets are prescription-only medicines. The only legal route to either in the UK is a consultation with a qualified prescriber who can assess whether treatment is appropriate for you, based on your BMI, health conditions, and any other medicines you take. For an overview of the licensed eligibility criteria, the tirzepatide tablet explainer and the weight-loss treatment overview both set out the key thresholds.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber on the same day it is submitted. There are no algorithms making clinical decisions. If treatment is approved, your prescription is dispensed from our GPhC-registered pharmacy (registration number 9012878, verifiable at the GPhC register) and dispatched the same day for free next-working-day delivery via DPD in plain packaging. There are no hidden fees and no subscription, each repeat order is independently reviewed. For a transparent breakdown of what is included in the price, the Mounjaro cost page covers that plainly.

If you are ready to find out which treatment suits your situation, you can start your free consultation today.